Matthias Gehringer

Matthias Gehringer studied chemistry at the Karlsruhe Institute of Technology (KIT), the Ecole Nationale Supérieure de Chimie de Montpellier (ENSCM), and the University of Heidelberg. He obtained his Ph.D. from the University of Tübingen where he worked on reversible and irreversible inhibitors of the protein kinase JAK3. As a postdoc at the Swiss Federal Institute of Technology (ETH) in Zürich, he focused on the total synthesis of complex natural products from the mycolactone family. In 2019, he was appointed as Assistant Professor for Medicinal Chemistry at the Institute of Pharmaceutical Sciences, University of Tübingen, and Associate Investigator in the Cluster of Excellence "Image Guided and Functionally Instructed Tumor Therapies" (iFIT). His research in the areas of Medicinal Chemistry and Chemical Biology is mainly dedicated to covalent protein kinase inhibitors and novel approaches for covalent targeting.